Evidence map›Paper›PMID 39097734›Full record

ArticleJournal of translational medicine2024

Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer.

Guanjun Li, Xiaohan Liu, Chunhui Gu, Guichuang Ma, Shaowei Li, Zhenfeng Ma, Yanqiu Xiong, Yu Jiang, Qiong Huang, Jianhua Wu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Guanjun Li *Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Xiaohan Liu *Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Chunhui Gu *Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Guichuang MaDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Shaowei LiDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Zhenfeng MaDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Yanqiu XiongDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Yu JiangDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Qiong HuangDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Jianhua WuDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Zhenzhen WuDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Wangjun LiaoDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Qijing WuDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China. wuqijingsmu@126.com.
Min ShiDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China. nfyyshimin@163.com.ORCID 0000-0003-0113-4089

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2022A1515011693Basic and Applied Basic Research Foundation of Guangdong Province 2023A1515110026Guangzhou Municipal Science and Technology Project SL2022A04J01902National Natural Science Foundation of China 82073325
6 · The paper itself

Abstract

backgroundAn increasing number of clinical studies have begun to explore combination strategies with immune checkpoint inhibitors, aiming to present new opportunities for overcoming anti-PD-1 treatment resistance in gastric cancer. Unfortunately, the exploration of certain immune checkpoint inhibitor combination strategies has yielded suboptimal results. Therefore, it is necessary to comprehensively analyze the expression patterns of immune checkpoints and identify optimal combination regimens of anti-PD-1 inhibitors with other immune checkpoint inhibitors.

methodsLeveraging single-cell RNA sequencing (scRNA-seq) and multivariate linear regression interaction models, we dissected the immune checkpoint expression characteristics of CD8

resultsInteraction analysis indicated that, among the known immune checkpoints, co-expression of NKG2A and PD-1 might exert a more profound inhibitory effect on the proliferative capacity of CD8

conclusionThis study unveiled two distinct ICEPs and the mutually exclusivity and co-occurrence characteristics of CD8

Indexed as

CD8-Positive T-LymphocytesDrug Resistance, NeoplasmImmune Checkpoint InhibitorsNK Cell Lectin-Like Receptor Subfamily CStomach NeoplasmsCell DifferentiationGene Expression Regulation, NeoplasticHumansImmune Checkpoint ProteinsProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsImmune Checkpoint ProteinsKLRC1 protein, humanNK Cell Lectin-Like Receptor Subfamily CProgrammed Cell Death 1 ReceptorGastric cancerImmune checkpointImmunotherapyMacrophageT cellTumor microenvironment

Identifiers

PMID39097734
PMCPMC11298088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.